Share Name Share Symbol Market Type Share ISIN Share Description
Fulham Sho LSE:FUL London Ordinary Share GB00B9F8VG44 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 18.25p 17.50p 19.00p 18.25p 18.25p 18.25p 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Travel & Leisure 8.3 0.0 0.0 - 104.07

Fulham Sho (FUL) Latest News

More Fulham Sho News
Fulham Sho Takeover Rumours

Fulham Sho (FUL) Share Charts

1 Year Fulham Sho Chart

1 Year Fulham Sho Chart

1 Month Fulham Sho Chart

1 Month Fulham Sho Chart

Intraday Fulham Sho Chart

Intraday Fulham Sho Chart

Fulham Sho (FUL) Discussions and Chat

Fulham Sho Forums and Chat

Date Time Title Posts
07/11/201617:25The Fulham Shore PLC22.00
26/7/201219:58Fulcrum Pharma - drug development to regulatory approval (1.1.07)631.00
21/2/200707:41FULCRUM IN PROFIT & GROWING1,807.00
17/4/200418:56Strong buy - FUL Pharma - profit and turnover up x 10 fold13.00
01/5/200308:14Fulcrum Pharma (FUL)1,061.00

Add a New Thread

Fulham Sho (FUL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Fulham Sho trades in real-time

Fulham Sho (FUL) Top Chat Posts

DateSubject
05/12/2016
08:20
Fulham Sho Daily Update: Fulham Sho is listed in the Travel & Leisure sector of the London Stock Exchange with ticker FUL. The last closing price for Fulham Sho was 18.25p.
Fulham Sho has a 4 week average price of 17.59p and a 12 week average price of 19.08p.
The 1 year high share price is 23p while the 1 year low share price is currently 15p.
There are currently 570,269,265 shares in issue and the average daily traded volume is 67,663 shares. The market capitalisation of Fulham Sho is £104,074,140.86.
07/11/2016
17:25
lbo: Tasty PLC just did a large fundraising which explains why it's share price has been falling all year. Is the same on the cards here?
28/4/2010
06:36
welsheagle: RNS Number : 9149K Fulcrum Pharma PLC 28 April 2010 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION (INCLUDING THE UNITED STATES, AUSTRALIA, CANADA AND JAPAN) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 28 April 2010 RECOMMENDED CASH OFFER by GOLD MEDAL ACQUISITIONS UK LIMITED for FULCRUM PHARMA PLC Summary · The boards of Gold Medal Acquisitions UK Limited ("Gold Medal UK") and Fulcrum Pharma plc ("Fulcrum Pharma" or the "Company") are pleased to announce the terms of a recommended cash offer, to be made by Gold Medal UK for the entire issued and to be issued share capital of Fulcrum Pharma (the "Offer"). · The Offer will comprise 5.85 pence in cash for each Fulcrum Pharma Share (the "Offer Price"). · The Offer values the entire issued and to be issued share capital of Fulcrum Pharma at approximately £11.56 million. · The Offer Price represents a premium of approximately: o 73 per cent. to the Closing Price of 3.375 pence per Fulcrum Pharma Share on 27 April 2010, being the last Business Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement.
28/4/2010
06:31
welsheagle: Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement.
19/1/2010
15:36
ianctaylor: I considered buying shares in this company today but decided not to in the end. The share price is not stable enough for me. I prefer to see a smoother, more consistent price movement. I hope the preliminary approach made to the company in mid-November 2009 results in some benefit to holders. For what it's worth, a fair value per share would seem to be about 7p, with 177,940,743 shares in issue.
14/7/2009
13:54
gimeabreak: Had a feeling the share price would hike soon it had crashed without justification so just getting back to a semblance of its true value, that spread though has prevented me from buying more so so frustrating.
24/6/2009
18:15
gimeabreak: Nice one scruff if only if only. Really though if you read through the final results they appear quite positive when other companies are in financial difficulties laying off staff going bust Fulcrums performance is very good,which makes me wonder why the share price has taken such a battering as trading in this stock has been none existant nobody buying nobody selling, some hidden agenda whatever, I've held this stock for years and years never seen a profit, looks like another few more are to come before I'm rich rich RICH RICH HHHAAAAAA YIKKKEEESSSSSSS another tablet please doc
23/4/2009
12:50
platts: mountain man:re your question: I have held ful now for over 4 years and frankly the share price goes nowhere. at the same time the company continues to improve its performance - Japan etc. I wonder what needs to happen for this company to fall out of its bunker. I have no intention to sell (it's to cheap to do so.) I don't believe in pumping a stock as other people seem to want to do (see above)
15/11/2007
07:13
buggy: Better late than never I suppose, but a profit warning is still a profit warning no matter how it is dressed. Market has not been fooled as shown by the current share price. ".... whilst Unicus has returned to profitability, the losses are greater than originally anticipated......" Oh well ... there is always next year. It appears that my strategy to sell down at par was right. Hopefully the next interims will give better pointer to future prospects. Still think this will be a great company if they will have focus on what is their core business. I think that the management strategy has been distracted over the last 2 years possibly aided by the successful acquisition and integration of Quadramed.
27/12/2006
21:19
buggy: gimeabreak, The total number of shares held by current directors is 16,118,989. This equates to about 12.54%. A sizeable chunk of the shares is held by PI (usually registered under norminee accounts Chase Norminee 9.39% etc). I never found it difficult buying the shares.I think that at the moment this share has not come under the gaze of the investment trusts... It is still too risky. The share price is languishing where it is because it seems like only PI has an interest in the shares currently .... and most of us are already fully loaded. After the next set of results .. if improvements continues apace then it may be a different story. There are shares available to buy at higher volumes, though they may have to pay a premuim to the current price ... which will of course move the price up.
07/5/2003
08:26
stocktrader: Looks like it's not all doom and gloom RNS Number:7775K Fulcrum Pharma PLC 07 May 2003 The following replaces the Interim Results announcement released 7 May 2003 at 0700 under RNS No 7648K. Bullet point four on the Highlights page should read "Group loss before exceptionals #313,000 (2002: #422,000 profit)" and not "Group loss after exceptionals #313,000 (2002: #422,000 profit)" as previously stated. The full amended text is below: For Immediate Release Wednesday, 7 May 2003 Fulcrum Pharma plc Interim Results for the six months to 28 February 2003 Fulcrum Pharma PLC (LSE: FUL), the independent drug development company, today announces its interim audited results for the six months ended 28 February 2003. Following the recent rise in the Group's share price and, in order to ensure that the Market remains informed, Fulcrum has decided, on the advice of its brokers, to bring forward the announcement of its interim results from 15 May to today, Wednesday, 7 May 2003. Highlights: * EU sales remain flat * US office fully established and operational * Japanese businesses on track: o new contracts won o specialist oncology contract research organisation set up * Group loss before exceptionals #313,000 (2002: #422,000 profit) * Strong cash position : #4.7 million * Dividend maintained at 0.2 pence per share * Management Strengthened: Dr Michael Carter to join the Board as Non Executive Director Commenting on the results Chairman, Prof. Sir Charles George said: "With the global economy remaining volatile, the importance of Fulcrum's balanced global strategy is clear. While our sales in the EU have been lower than expected, our US and Japanese businesses have performed in line with internal expectations and remain well placed to provide revenue streams in coming years. "Your Board is confident that Fulcrum is positioned to grow in the future outsourcing market as clients and investors recognise the value of strategic outsourcing rather than burning cash on building their own development infrastructure." For further information, please contact : Fulcrum Pharma PLC Tel: 0870 710 7152 Jon Court, Chief Executive Buchanan Communications Tel: 07956 597 099 Nicola How / Louise Bolton Tel: 0207 466 5000 FULCRUM PHARMA PLC Interim Results for the six months ended 28 February 2003 REPORT OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER INTRODUCTION I am pleased to announce the Interim results for the six months to 28 February 2003. The period under review continues to see the global pharmaceutical market operating under increasingly difficult economic conditions. In Europe, Fulcrum's customers have been slower to commit to new contracts for outsourced work. Furthermore, the difficult financing environment in the biotech sector has forced some companies to conserve cash and reduce the quantity of work outsourced. These conditions have impacted our sales, particularly in the EU, where changes in client strategy have resulted in the termination of two significant contracts. As a result Fulcrum has experienced its first loss. However, in light of the change in market conditions, the Management team has been realigning its EU selling strategy with the consequence that a high number of new clients have been won recently. The Company continues to roll out its plans for the US and Japan. In both areas we are experiencing better trading conditions for Fulcrum's services and this is creating new selling opportunities through marketing Preferred Supplier Arrangements ("PSA"). Progress in these areas is described in the operational report below. FINANCIAL REVIEW The results for the six months ended 28 February 2003 show a loss before tax and exceptional items of #313,000 (2002: profit of #422,000). During the period Fulcrum has established its US subsidiary and completed the restructuring of the Japanese business into subsidiaries. These activities have incurred anticipated exceptional costs of #390,000. The US and Japanese results were in line with expectations. It has been the lower than expected sales in the EU, combined with the costs of Fulcrum's growth plans, which have resulted in the loss before tax and exceptional items of #313,000. The loss is stated after an exchange loss of #42,000 (2002: exchange gain of #50,000) and non-recurring costs of #275,000 have been incurred. The latter costs are related to recruitment, business development and office relocation. Fulcrum's cash position remains strong at #4.7 million. DIVIDEND The dividend has been maintained at 0.2 pence per share reflecting your Directors' confidence in Group's future. OPERATIONAL REVIEW Last year I described our plan for expansion across Europe, US and Japan. These plans were designed to put in place the capabilities and resources critical to the long-term prospects of the Company. I am pleased to report that Fulcrum has made good progress in all three areas in the implementation of this plan. The solid building blocks now in place will be key to addressing the sales performance in the first half of the year and building for the future. A summary of this plan and how we have progressed since our preliminary statement is outlined below: * Scale up of the UK/European operation: Fulcrum has been successful in attracting talented and experienced drug developers to the Company. Therapeutic area expertise, project management resources and capabilities in the management of outsourcing have all been strengthened. These skill sets are critical to selling the business model to our clients. Despite the difficult trading conditions there has been a good conversion on small bids and new customers have been won. We are working to extend these new relationships into longer term contracts. * Globalisation to meet the needs of our clients: We have used our global resources to develop new business and serve existing clients in EU, US and Japan. US: I am pleased to report that our US office under the leadership of Dr Bruce McCreedy now has a high quality team of drug developers in place and has won contracts from new clients within its first half year of operation. The first US office has been established in North Carolina where Fulcrum can access new clients, the suppliers required to execute its business model and an excellent pool of talent for future recruitment. Since the US market represents more than half of the global R&D spend this is an important development for Fulcrum. Japan: We are delighted that we have been able to recruit Mr Fujimaru (formerly a senior executive and Board member of EPS, one of Japan's leading service providers) to lead Niphix KK. Niphix is Fulcrum's newly created, specialist oncology Contract Research Organisation ("CRO"). It is our aim that Niphix will provide oncology services to the Pharma community which, in Japan, is an area still poorly served. Fulcrum's CRO has already gained its first contract and with Mr Fujimaru's recent experience of setting up and running a successful service company in Japan we have every confidence in this being the first of many client wins. Niphix is an important piece of Fulcrum's mid to long term strategy to create shareholder value. Our first Japanese company, Fulcrum Pharma KK continues to provide project design and management services to Japanese and European clients and retains its reputation as a supplier of specialist oncology drug development services. * Development of Partnership or Preferred Supplier Arrangements ("PSA"): Fulcrum continues to use the PSA concept as an effective selling tool for its core development services. The PSA concept is where Fulcrum makes an equity or other capital investment into a client company in return for preferred supplier status to manage the development of a number of client products. As reported last year, while this has been useful to access clients it has been difficult to implement due to the volatility in the Biotech and Pharma industries. Management has therefore taken steps to optimise the conditions for success and are incubating a PSA venture within Fulcrum and this could ultimately provide a portfolio of contracts for Fulcrum's core business. It is intended to spin out this venture within 12 months and a team of senior executives has been recruited. Some of the #3,250,000 funds raised last year are being invested to develop this PSA. This is another example of Fulcrum diversifying within its market to create value downstream for our investors. * Strategic Services: These have been further developed in order to provide new products in Chemistry Manufacturing & Controls (CMC) and preclinical development. These products have been used to increase access to new and existing clients and facilitate cross-selling. For example, contracts are being won in Japan, which utilise our technical and CMC expertise and resources in our EU and US Offices. STRENGTHENING THE BOARD I am delighted that Dr Michael Carter has agreed to join our Board. Dr Carter brings important industry and City experience. He has gained these skill sets from a range of directorship roles in start up Pharma companies in Europe and the US, a venture partner role with Schroder Ventures Life Sciences and through commercial roles in big Pharma. PROSPECTS The current trading conditions, which have impacted sales in the first half, will have a knock on effect in the second half of the year. We expect sales to improve in the future and I look forward to reporting a positive outcome for the full year - however this will be significantly below current market expectations. With the global economy remaining volatile, the importance of Fulcrum's balanced global strategy is clear. While our sales in the EU have been lower than expected, our US and Japanese businesses are performing in line with internal expectations and remain well placed to provide revenue streams in coming years. Your Board is confident that Fulcrum remains well positioned to grow in the future outsourcing market as clients and investors recognise the value of strategic outsourcing rather than burning cash on building their own development infrastructure. Further, the incubation of a Preferred Supplier Arrangement within Fulcrum has the potential to provide upside to our sales and further mitigate the risks associated with the current market. FULCRUM PHARMA PLC
Fulham Sho share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20161206 05:46:15